BMY - Bristol Myers completes acquisition of MyoKardia

Bristol Myers Squibb (BMY) has successfully completed its acquisition of MyoKardia (MYOK) in an all cash transaction for ~$13.1B.With the completion of the acquisition, MyoKardia shares have ceased trading on Nasdaq and the company now a wholly-owned subsidiary of Bristol Myers. Through the transaction, BMY gains mavacamten, a potential cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy.A NDA for mavacamten for obstructive HCM is expected to be submitted in Q1 2021.See below MyoKardia’s promising pipeline:Previously: Bristol Myers Squibb to acquire Myokardia for $13.1B in cash (Oct. 5)

For further details see:

Bristol Myers completes acquisition of MyoKardia